Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALNY POWR Grades
- ALNY scores best on the Value dimension, with a Value rank ahead of 64.74% of US stocks.
- ALNY's strongest trending metric is Value; it's been moving up over the last 206 days.
- ALNY's current lowest rank is in the Momentum metric (where it is better than 5.09% of US stocks).
ALNY Stock Summary
- ALNY's price/sales ratio is 27.37; that's higher than the P/S ratio of 92.53% of US stocks.
- With a year-over-year growth in debt of 70.1%, Alnylam Pharmaceuticals Inc's debt growth rate surpasses 87.83% of about US stocks.
- Revenue growth over the past 12 months for Alnylam Pharmaceuticals Inc comes in at 99.68%, a number that bests 94.23% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are EXAS, NICE, CHKP, HZNP, and NET.
- ALNY's SEC filings can be seen here. And to visit Alnylam Pharmaceuticals Inc's official web site, go to www.alnylam.com.
ALNY Stock Price Chart Interactive Chart >
ALNY Price/Volume Stats
|Current price||$135.89||52-week high||$178.41|
|Prev. close||$135.70||52-week low||$119.29|
|Day high||$136.69||Avg. volume||635,861|
|50-day MA||$138.10||Dividend yield||N/A|
|200-day MA||$139.67||Market Cap||15.97B|
Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio
Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.
ALNY Latest News Stream
|Loading, please wait...|
ALNY Latest Social Stream
View Full ALNY Social Stream
Latest ALNY News From Around the Web
Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Photo by libre de droit/iStock via Getty ImagesDicerna Pharmaceuticals (DRNA) specializes in RNAi (RNA interference) therapies. This has become a major field for pharmaceutical companies in the last few years and promises to be a value generator for this coming decade. I am updating my thesis because when I wrote...
Evercore ISI Stick to Their Buy Rating for Alnylam Pharmaceuticals
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). These data were presented at the American Society of Pediatric Nephrology (ASPN)/Pediatric Academic Societies (PAS) virtual meeting being held on April 30–May 4, 2021.
Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.
Alnylam Pharmaceuticals (ALNY): Q1 Non-GAAP EPS of -$1.64 misses by $0.24; GAAP EPS of -$1.71 beats by $0.06.Revenue of $177.57M (+78.5% Y/Y) beats by $9.07M.Press Release...
ALNY Price Returns
Continue Researching ALNYWant to do more research on Alnylam Pharmaceuticals Inc's stock and its price? Try the links below:
Alnylam Pharmaceuticals Inc (ALNY) Stock Price | Nasdaq
Alnylam Pharmaceuticals Inc (ALNY) Stock Quote, History and News - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) Stock Price and Basic Information | MarketWatch